Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

A phase I, open-label clinical study to evaluate the safety, tolerability, and efficacy of LUCAR-G39D, a dual-targeted cell preparation targeting CD19/CD20, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Trial Details

NCT ID
NCT06395870
Phase
PHASE1
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • LUCAR-G39D cells product
Locations (sample)
  • Hefei, Anhui, China|31.86389,117.28083
  • Tianjin, China|39.14222,117.17667

Key Eligibility Criteria

  • Subjects have fully understood the possible risks and benefits of participating in this study, are willing to follow and able to complete all trial…
  • Aged 18-75 years (inclusive).
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Histologically confirmed B-cell non-Hodgkin Lymphoma that expresses at least one of CD19/CD20.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →